- Auris Medical Holding (NASDAQ:EARS) announces that its affiliate Altamira Medica has started preparations to conduct a study with its Bentrio nasal spray for protection against airborne viruses and allergens in India.
- The study will seek to evaluate the efficacy of Bentrio in the prevention and treatment of acute Covid-19 and shall start recruitment in Q3 2021 subject to regulatory and ethics committee approval.
- Shares up marginally during premarket trading.
Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Recommended For You
About CYTO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CYTO | - | - |
Altamira Therapeutics Ltd. |